skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

This white paper examines the landscape of new drug development and clinical trial activity in heart failure, which affects 5.8 Americans and 23 million people globally. In the past five years, just one new/novel drug has been registered with a regulatory authority for approval, and three other compounds with previous approvals in other indications such as hypertension and angina were also registered for heart failure to see where the future of treatment could lead us.

 

  • The number of heart failure drugs in development by pharma company
  • Phase II and Phase III pipeline drugs, the company developing them and the mechanism of action for each
  • Which companies are leading in the number of Phase III as well as total trials
  • The current state of cell therapies in development, and how their developers could best convince the healthcare community of their viability
  • The countries that are hosting the most clinical trial activity
Innovation In Heart Failure Drug Development

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: